Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Patterns of care for patients with metastatic bone disease in solid tumors – a cross-sectional study (SAKK 95/16)

Date

28 Sep 2019

Session

Poster Display session 1

Presenters

Michael Mark

Citation

Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265

Authors

M.T. Mark1, B.J.K. Thuerlimann2, K. Ribi3, C. schaer4, D. Dietrich4, U. Zuerrer5, R. von Moos1

Author affiliations

  • 1 Oncology/hematology, Kantonsspital Graubünden, 7000 - Chur/CH
  • 2 Oncology/hematology, Brustzentrum Kantonsspital St. Gallen, 9007 - St. Gallen/CH
  • 3 Quality Of Life Office, IBCSG International Breast Cancer Study Group, 3008 - Bern/CH
  • 4 Coordinating Center, SAKK, 3008 - Bern/CH
  • 5 Onkologie, Kantonsspital Winterthur, 8401 - Winterthur/CH
More

Resources

Background

The best use of bone targeted agents (BTAs), i.e. how patients (pts) profit most from treatment, optimal timing of treatment start and frequency of administration as well as duration of treatment is unclear to date.

Methods

Physicians were asked to indicate the criteria they use for the indication and administration of BTAs in pts with bone metastases from solid tumors in Switzerland (physician-related outcomes, PO) during a period of 3 months. Patterns of care (POC) was assessed by questions about reasons for BTA administration, treatment pattern, patient characteristics, and actual treatment. Pts completed a pain and bone-pain related quality of life questionnaire.

Results

PO: Most of the physicians reported to start treatment with BTAs according to current guidelines (70.9%, 61/86). A smaller proportion would first assess the risk (high vs low) for developing skeletal-related events (SREs) to decide about treatment initiation (24.4%, 21/86). Factors contributing to define high risk were former SREs (89.5%, 77/86), lytic bone metastases (87.2%, 75/86), and high burden of disease (67.4%, 58/86), respectively. POC: The majority of the pts have been treated with BTAs immediately after the diagnosis of bone metastases (73.6%, 307/417). The main reasons for treatment with BTAs were high risk of bone complications (43%, 132/307), bone pain (21.8%, 67/307), and location of bone metastases (10.1%, 31/307), respectively. Denosumab was the most frequently used BTA (78.5%; 241/307), and a 3-4 week interval was most common (88.9%; 273/307). SREs were reported in 8.5% of treated vs 7.3% of non-treated pts, and were similar in pts rated as low or as high risk (about 8%).

Conclusions

The majority of the pts was treated according to current guideline recommendations with regard to start and interval of BTA treatment. The number of SREs was low irrespective of BTA treatment or risk classification for SREs, which may reflect a high impact of systemic cancer treatment on SRE reduction, or a selection of the pts according to risk factors not defined as the ones in the literature.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

SAKK.

Funding

Amgen.

Disclosure

M.T. Mark: Advisory / Consultancy: Roche; Advisory / Consultancy: MSD; Advisory / Consultancy: Böhringer Ingelheim; Advisory / Consultancy: Takeda; Advisory / Consultancy: BMS. B.J.K. Thuerlimann: Advisory / Consultancy, Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options: Roche; Shareholder / Stockholder / Stock options: Novartis; Advisory / Consultancy: Lilly; Advisory / Consultancy: Amgen; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Pfizer. R. von Moos: Advisory / Consultancy: amgen; Advisory / Consultancy: BMS; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Pfizer. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings